Akkermansia muciniphila in infectious disease: A new target for this next-generation probiotic?
Loading...
Date
2024-03-15
Authors
Keane, Jonathan M.
Cazzaniga, Monica
Gahan, Cormac G. M.
Journal Title
Journal ISSN
Volume Title
Publisher
SAGE Publishing
Published Version
Abstract
The common gastrointestinal commensal Akkermansia muciniphila is a mucin-degrading bacterium that is greatly reduced in individuals consuming a high-fat diet. Increasing evidence from a variety of clinical and pre-clinical studies suggests that oral supplementation with Akkermansia can improve metabolic health and moderate systemic inflammation. We and others have demonstrated a role for Akkermansia administration in protection against infectious disease and the outcome from sepsis. Very recent studies have indicated the molecular mechanisms by which A. muciniphila may interact with the host to influence systemic immune-regulation and control of microbial pathogenesis. Here we consider recent studies which demonstrate the efficacy of this potential next-generation probiotic in animal models of Salmonella Typhimurium, Listeria monocytogenes and Clostridioides difficile as well as influenza virus and phlebovirus. The potential mechanisms by which A. muciniphila may influence local and systemic immune responses are discussed.
Description
Keywords
Akkermansia muciniphila , Infection , Sepsis , Inflammation , Listeria
Citation
Keane, J. M., Cazzaniga, M., Gahan, C. G. M. (2024) 'Akkermansia muciniphila in infectious disease: A new target for this next-generation probiotic?', Science Progress, 107(1), pp. 1-7.
https://doi.org/10.1177/0036850424123115